MARKET

CBPO

CBPO

China Biologic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

110.50
-0.09
-0.08%
After Hours: 110.50 0 0.00% 16:00 09/25 EDT
OPEN
110.16
PREV CLOSE
110.59
HIGH
110.97
LOW
110.00
VOLUME
91.03K
TURNOVER
--
52 WEEK HIGH
119.44
52 WEEK LOW
97.91
MARKET CAP
4.26B
P/E (TTM)
27.98
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2020 Results - Earnings Call Transcript
China Biologic Products Holdings, Inc. (NASDAQ:CBPO) Q2 2020 Results Earnings Conference Call August 18, 2020, 07:30 AM ET Company Participants Philip Lisio - The Foote Group Joseph Chow - Chairman and Chief Executive Officer Ming Yin - Senior Vice President Ming Yang - Chief Financial Officer Conference Call Participants Jason Liu - Credit Suisse Stephanie Hanna - Dealreporter Presentation Operator Good day and good evening and welcome to the China Biologic Second Quarter 2020 Earnings Call.
Seeking Alpha - Transcript · 08/18 16:49
Update on China Biologic Products Q2 earnings
China Biologic Products ([[CBPO]] -1.9%) Q2 reports total sales of $111.1M (-18.1% Y/Y).Gross profit decreased by 16.0% to $76.4M.Income from operations decreased by 11.4% to $42.7M from $48.2 last year.Non-GAAP
Seekingalpha · 08/18 16:29
China Biologic Reports Financial Results for the Second Quarter of 2020
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the second quarter of 2020.
PR Newswire · 08/17 21:30
China Biologic Products EPS misses by $0.17
China Biologic Products (CBPO): Q2 Non-GAAP EPS of $1.11 misses by $0.17; GAAP EPS of $0.91.Revenue of $111.1M (-18.1% Y/Y)Press Release
Seekingalpha · 08/17 20:32
China Biologic Products Q2 EPS $1.11 Misses $1.28 Estimate, Sales $111.10M Down From $135.70M YoY
China Biologic Products (NASDAQ:CBPO) reported quarterly earnings of $1.11 per share which missed the analyst consensus estimate of $1.28 by 13.28 percent. This is a 10.48 percent decrease over earnings of $1.24 per
Benzinga · 08/17 20:31
The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs
Benzinga · 08/16 13:30
China Biologic Products to Report Second Quarter 2020 Financial Results
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its second quarter 2020 financial results o
PR Newswire · 08/10 12:00
5 Profitable Companies With a Margin of Safety
Comcast makes the list Continue reading...
GuruFocus.com · 07/13 16:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CBPO. Analyze the recent business situations of China Biologic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CBPO stock price target is 101.78 with a high estimate of 115.00 and a low estimate of 77.00.
EPS
Institutional Holdings
Institutions: 131
Institutional Holdings: 13.88M
% Owned: 35.97%
Shares Outstanding: 38.58M
TypeInstitutionsShares
Increased
32
2.33M
New
30
-157.86K
Decreased
29
500.05K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Chief Executive Officer/Director
Joseph Chow
Chief Financial Officer
Ming Yang
Director
Hui Li
Director
Yue'e Zhang
Independent Director
Yungang Lu
Independent Director
Qi Ning
Independent Director
Sean Shao
Independent Director
Xiaosheng Shao
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CBPO
China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company's products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of China Biologic Products Holdings Inc stock information, including NASDAQ:CBPO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBPO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBPO stock methods without spending real money on the virtual paper trading platform.